Cargando…
Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
AIMS : The increasing prevalence of ischaemic stroke (IS) can partly be explained by the likewise growing number of patients with chronic kidney disease (CKD). Risk scores have been developed to identify high-risk patients, allowing for personalized anticoagulation therapy. However, predictive perfo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046502/ https://www.ncbi.nlm.nih.gov/pubmed/33769473 http://dx.doi.org/10.1093/eurheartj/ehab059 |
_version_ | 1783678864369647616 |
---|---|
author | de Jong, Ype Fu, Edouard L van Diepen, Merel Trevisan, Marco Szummer, Karolina Dekker, Friedo W Carrero, Juan J Ocak, Gurbey |
author_facet | de Jong, Ype Fu, Edouard L van Diepen, Merel Trevisan, Marco Szummer, Karolina Dekker, Friedo W Carrero, Juan J Ocak, Gurbey |
author_sort | de Jong, Ype |
collection | PubMed |
description | AIMS : The increasing prevalence of ischaemic stroke (IS) can partly be explained by the likewise growing number of patients with chronic kidney disease (CKD). Risk scores have been developed to identify high-risk patients, allowing for personalized anticoagulation therapy. However, predictive performance in CKD is unclear. The aim of this study is to validate six commonly used risk scores for IS in atrial fibrillation (AF) patients across the spectrum of kidney function. METHODS AND RESULTS : Overall, 36 004 subjects with newly diagnosed AF from SCREAM (Stockholm CREAtinine Measurements), a healthcare utilization cohort of Stockholm residents, were included. Predictive performance of the AFI, CHADS(2), Modified CHADS(2), CHA(2)DS(2)-VASc, ATRIA, and GARFIELD-AF risk scores was evaluated across three strata of kidney function: normal kidney function [estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m(2)], mild CKD (eGFR 30–60 mL/min/1.73 m(2)), and advanced CKD (eGFR <30 mL/min/1.73 m(2)). Predictive performance was assessed by discrimination and calibration. During 1.9 years, 3069 (8.5%) patients suffered an IS. Discrimination was dependent on eGFR: the median c-statistic in normal eGFR was 0.75 (range 0.68–0.78), but decreased to 0.68 (0.58–0.73) and 0.68 (0.55–0.74) for mild and advanced CKD, respectively. Calibration was reasonable and largely independent of eGFR. The Modified CHADS(2) score showed good performance across kidney function strata, both for discrimination [c-statistic: 0.78 (95% confidence interval 0.77–0.79), 0.73 (0.71–0.74) and 0.74 (0.69–0.79), respectively] and calibration. CONCLUSION : In the most clinically relevant stages of CKD, predictive performance of the majority of risk scores was poor, increasing the risk of misclassification and thus of over- or undertreatment. The Modified CHADS(2) score performed good and consistently across all kidney function strata, and should therefore be preferred for risk estimation in AF patients. |
format | Online Article Text |
id | pubmed-8046502 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-80465022021-04-21 Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function de Jong, Ype Fu, Edouard L van Diepen, Merel Trevisan, Marco Szummer, Karolina Dekker, Friedo W Carrero, Juan J Ocak, Gurbey Eur Heart J Clinical Research AIMS : The increasing prevalence of ischaemic stroke (IS) can partly be explained by the likewise growing number of patients with chronic kidney disease (CKD). Risk scores have been developed to identify high-risk patients, allowing for personalized anticoagulation therapy. However, predictive performance in CKD is unclear. The aim of this study is to validate six commonly used risk scores for IS in atrial fibrillation (AF) patients across the spectrum of kidney function. METHODS AND RESULTS : Overall, 36 004 subjects with newly diagnosed AF from SCREAM (Stockholm CREAtinine Measurements), a healthcare utilization cohort of Stockholm residents, were included. Predictive performance of the AFI, CHADS(2), Modified CHADS(2), CHA(2)DS(2)-VASc, ATRIA, and GARFIELD-AF risk scores was evaluated across three strata of kidney function: normal kidney function [estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m(2)], mild CKD (eGFR 30–60 mL/min/1.73 m(2)), and advanced CKD (eGFR <30 mL/min/1.73 m(2)). Predictive performance was assessed by discrimination and calibration. During 1.9 years, 3069 (8.5%) patients suffered an IS. Discrimination was dependent on eGFR: the median c-statistic in normal eGFR was 0.75 (range 0.68–0.78), but decreased to 0.68 (0.58–0.73) and 0.68 (0.55–0.74) for mild and advanced CKD, respectively. Calibration was reasonable and largely independent of eGFR. The Modified CHADS(2) score showed good performance across kidney function strata, both for discrimination [c-statistic: 0.78 (95% confidence interval 0.77–0.79), 0.73 (0.71–0.74) and 0.74 (0.69–0.79), respectively] and calibration. CONCLUSION : In the most clinically relevant stages of CKD, predictive performance of the majority of risk scores was poor, increasing the risk of misclassification and thus of over- or undertreatment. The Modified CHADS(2) score performed good and consistently across all kidney function strata, and should therefore be preferred for risk estimation in AF patients. Oxford University Press 2021-03-26 /pmc/articles/PMC8046502/ /pubmed/33769473 http://dx.doi.org/10.1093/eurheartj/ehab059 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research de Jong, Ype Fu, Edouard L van Diepen, Merel Trevisan, Marco Szummer, Karolina Dekker, Friedo W Carrero, Juan J Ocak, Gurbey Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function |
title | Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function |
title_full | Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function |
title_fullStr | Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function |
title_full_unstemmed | Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function |
title_short | Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function |
title_sort | validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046502/ https://www.ncbi.nlm.nih.gov/pubmed/33769473 http://dx.doi.org/10.1093/eurheartj/ehab059 |
work_keys_str_mv | AT dejongype validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction AT fuedouardl validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction AT vandiepenmerel validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction AT trevisanmarco validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction AT szummerkarolina validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction AT dekkerfriedow validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction AT carrerojuanj validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction AT ocakgurbey validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction |